XRAY is a reliable source of cancer-related news and information.
XRAY Quarterly Digest
FORCE developed our XRAY-Behind the Headlines program to help people separate relevant cancer news from hype by providing honest evaluations of cancer research reported in the media. Originally developed for young breast cancer survivors, we now have XRAY portals focused on Metastatic Breast Cancer, Ovarian Cancer and Pancreatic Cancer. Soon we will be adding a Prostate Cancer portal.
 
The XRAY Quarterly Digest provides a compilation of XRAY reviews published over the last three months.
How does a breast cancer diagnosis affect young women?
 
Most young women with breast cancer are working one year after diagnosis. However, women with greater financial stress face greater challenges after a breast cancer diagnosis. Read behind the cancer headlines about employment and job satisfaction.

Read the Review
 
Olaparib for metastatic pancreatic patients with BRCA mutations gains FDA approval
 

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy. In December 2019, based on the results of this study, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation. Read behind the headlines to learn more about this treatment.


Read the Review
A new treatment for metastatic breast cancer shows promise  
 
A promising new drug called tucatinib shows improved survival for people with HER2-positive metastatic breast cancer, even with brain and other metastases.  Read headlines about this breaking news from the 2019 San Antonio Breast Cancer Symposium.

Read the Review
 
Does exercise reduce breast cancer risk?

XRAY looks behind the headlines at a study showing that even modest exercise may reduce breast cancer, risk regardless of family history.


Read the Review
 
A new drug to treat newly-diagnosed ovarian cancer

This study looked at the usefulness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly-diagnosed ovarian cancer patients who had a response to chemotherapy. Read behind the headlines about how niraparib increases progression-free survival.

Read the Review
 
A new blood test may predict which patients are at highest risk for recurrence

This study looked at whether a blood test for tumor DNA (called circulating tumor DNA or ctDNA) can find people with recurrence earlier than current clinical practice.


Read the Review

 
                   .  
 
 
Facing Our Risk of Cancer Empowered, 16057 Tampa Palms Blvd. W #373, Tampa, FL 33647
 http://go.pardot.com/webmail/293442/625494887/fdbaed419814cf423724fce3627da4c2fbc7f637e3023744c6672bd54855c820 update preferences http://go.pardot.com/unsubscribe/u/293442/fdbaed419814cf423724fce3627da4c2fbc7f637e3023744c6672bd54855c820/625494887

FORCE®, FORCE FACING OUR RISK OF CANCER EMPOWERED®, JOINING FORCES AGAINST HEREDITARY CANCER®, PREVIVOR® and the FORCE Ribbon Design are registered trademarks of FORCE-Facing Our Risk of Cancer Empowered, Inc. in the United States. Unauthorized reproduction or use of FORCE’s trademarks is prohibited.